Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

71.47 -0.54 (-0.75%)
Streaming Delayed Price Updated: 10:27 AM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gold Down Over 3%; Rigetti Computing Shares Spike Higher ↗
 
Via Benzinga
News headline image
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October ↗
 
Via Benzinga
Topics Economy
News headline image
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug ↗
BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel. 
Via Investor's Business Daily
News headline image
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market ↗
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality. 
Via Benzinga
News headline image
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market ↗
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies. 
Via Benzinga
News headline image
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
3 Top Stocks That Could Still Rocket Higher in 2024 ↗
Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
Via The Motley Fool
News headline image
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease ↗
BridgeBio Pharma shared new data showing that acoramidis reduced mortality and cardiovascular hospitalizations by 42% in its Phase 3 ATTRibute-CM study for ATTR-CM. FDA decision expected in November... 
Via Benzinga
News headline image
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition ↗
BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol production and reductions in key... 
Via Benzinga
News headline image
BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Patchy And Still Patchy In The Short Term ↗
In the very short term, I would say the further downside is likely but not for long. These are not ideal conditions, so either sit it out or make sure you take your profits early. 
Via Talk Markets
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Is BridgeBio Pharma Stock Trading Higher On Friday? ↗
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants... 
Via Benzinga
News headline image
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Marvell Technology Posts Upbeat Sales, Joins MongoDB, Intel, MINISO Group And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.